Internisticamente - 5 settembre 2025 - Episodio 2

From Internisticamente - Le novità a 360° in Medicina Interna · 00:15:42

Show by Manciobo

Secondo episodio di aggiornamento clinico-scientifico in Medicina Interna e dintorni...Temi trattati:- parkinsonismi atipici- basse dosi di DOAC (apixaban e rivaroxaban) nella prevenzione delle recidive di tromboembolismo venoso nei soggetti ad elevato rischio - delirium post-operatorioKeywords: neurodegenerative disorders, atypical Parkinsonism, DOAC, venous thromboembolism, post-operative delirium, prevention strategies, clinical guidelines, patient care.Summary: In this episode of "Internisticamente", Dr. Stefano Mancini discusses three critical topics in clinical practice: atypical neurodegenerative disorders, the use of low-dose DOACs for venous thromboembolism, and strategies for preventing post-operative delirium. The conversation emphasizes the importance of accurate diagnosis, effective treatment protocols, and preventive measures in enhancing patient care.Takeaways:Atypical neurodegenerative disorders require careful diagnosis.Anamnesis and imaging are crucial for identifying atypical disorders.Low doses of DOACs can be effective and safer for patients.Risk stratification is essential for preventing post-operative delirium.Cognitive decline in Parkinson's tends to appear later in the disease.Patients with atypical disorders may show early postural instability.Low-dose DOACs have shown promising results in recent studies.Preventing delirium is more effective than treating it post-operatively.Immediate assistance helps patients regain autonomy after surgery.Environmental interaction is vital for patient recovery.Navigating Atypical Neurodegenerative DisordersThe Efficacy of Low-Dose DOACs"A careful anamnesis is crucial for diagnosis.""Imaging plays a key role in diagnosis.""Low doses of DOACs show promising results."

More episodes of Internisticamente - Le novità a 360° in Medicina Interna

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.